Abstrakt

Przypisy

• 1. Ajuwon K.M., Spurlock M.E.: Adiponectin inhibits LPS-inducedNF-κB activation and IL-6 production and increases PPARγ2 expressionin adipocytes. Am. J. Physiol. Regul. Integr. Comp. Physiol.,2005; 288: R1220-R1225 2 Assiri A.M., Kamel H.F., Hassanien M.F.: Resistin, visfatin, adiponectin,and leptin: risk of breast cancer in pre- and postmenopausalsaudi females and their possible diagnostic and predictive implicationsas novel biomarkers. Dis. Markers, 2015; 2015: 253519
  Google Scholar
• 2. diabetes mellitus and impaired glucose tolerance. Diabetes Res.Clin. Pract., 2007; 76: 24-29
  Google Scholar
• 3. Barb D., Williams C.J., Neuwirth A.K., Mantzoros C.S.: Adiponectinin relation to malignancies: a review of existing basic research andclinical evidence. Am. J. Clin. Nutr., 2007; 86: s858-s866 4 Bokarewa M., Nagaev I., Dahlberg L., Smith U., Tarkowski A.:Resistin, an adipokine with potent proinflammatory properties. J.Immunol., 2005; 174: 5789-5795
  Google Scholar
• 4. J. Cell. Mol. Med., 2010; 14: 1419-1431
  Google Scholar
• 5. Bråkenhielm E., Veitonmäki N., Cao R., Kihara S., Matsuzawa Y.,Zhivotovsky B., Funahashi T., Cao Y.: Adiponectin-induced antiangiogenesisand antitumor activity involve caspase-mediated endothelialcell apoptosis. Proc. Natl. Acad. Sci. USA, 2004; 101: 2476-2481
  Google Scholar
• 6. Catalán V., Gómez-Ambrosi J., Rodríguez A., Frühbeck G.: Adiposetissue immunity and cancer. Front. Physiol., 2013; 4: 275
  Google Scholar
• 7. Chia V.M., Newcomb P.A., Lampe J.W., White E., Mandelson M.T.,McTiernan A., Potter J.D.: Leptin concentrations, leptin receptorpolymorphisms, and colorectal adenoma risk. Cancer Epidemiol.Biomarkers Prev., 2007; 16: 2697-2703
  Google Scholar
• 8. Curat C.A., Wegner V., Sengenès C., Miranville A., Tonus C., BusseR., Bouloumié A.: Macrophages in human visceral adipose tissue: increasedaccumulation in obesity and a source of resistin and visfatin.Diabetologia, 2006; 49: 744-747
  Google Scholar
• 9. Dalamaga M., Karmaniolas K., Panagiotou A., Hsi A., ChamberlandJ., Dimas C., Lekka A., Mantzoros C.S.: Low circulating adiponectinand resistin, but not leptin, levels are associated with multiplemyeloma risk: a case-control study. Cancer Causes Control,2009; 20: 193-199
  Google Scholar
• 10. De Pergola G., Silvestris F.: Obesity as a major risk factor forcancer. J. Obes., 2013; 2013: 291546
  Google Scholar
• 11. Dogru T., Sonmez A., Tasci I., Bozoglu E., Yilmaz M.I., Genc H.,Erdem G., Gok M., Bingol N., Kilic S., Ozgurtas T., Bingol S.: Plasmavisfatin levels in patients with newly diagnosed and untreated type
  Google Scholar
• 12. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., RebeloM., Parkin D.M., Forman D., Bray F.: Cancer incidence and mortalityworldwide: sources, methods and major patterns in GLOBOCAN 2012 Int. J. Cancer, 2015; 136: E359-E386
  Google Scholar
• 13. Filippatos T.D., Derdemezis C.S., Kiortsis D.N., Tselepis A.D., ElisafM.S.: Increased plasma levels of visfatin/pre-B cell colony-enhancingfactor in obese and overweight patients with metabolic syndrome.J. Endocrinol. Invest., 2007; 30: 323-326
  Google Scholar
• 14. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M.,Kishimoto K., Matsuki Y., Murakami M., Ichisaka T., Murakami H.,Watanabe E., Takagi T., Akiyoshi M., Ohtsubo T., Kihara S., et al.:Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science, 2005; 307: 426-430
  Google Scholar
• 15. Gan A.M., Butoi E.D., Manea A., Simion V., Stan D., ParvulescuM.M., Calin M., Manduteanu I., Simionescu M.: Inflammatory effectsof resistin on human smooth muscle cells: up-regulation of fractalkineand its receptor, CX3CR1 expression by TLR4 and Gi-proteinpathways. Cell Tissue Res., 2013; 351: 161-174
  Google Scholar
• 16. Garten A., Petzold S., Barnikol-Oettler A., Körner A., ThaslerW.E., Kratzsch J., Kiess W., Gebhardt R.: Nicotinamide phosphoribosyltransferase(NAMPT/PBEF/visfatin) is constitutively releasedfrom human hepatocytes. Biochem. Biophys. Res. Commun., 2010;391: 376-381
  Google Scholar
• 17. Gonzalez-Perez R.R., Xu Y., Guo S., Watters A., Zhou W., LeibovichS.J.: Leptin upregulates VEGF in breast cancer via canonic andnon-canonical signalling pathways and NFκB/HIF-1α activation.Cell. Signal., 2010; 22: 1350-1362
  Google Scholar
• 18. Hlavna M., Kohut L., Lipkova J., Bienertova-Vasku J., DostalovaZ., Chovanec J., Vasku A.: Relationship of resistin levels with endometrialcancer risk. Neoplasma, 2011; 58: 124-128
  Google Scholar
• 19. Ishikawa M., Kitayama J., Kazama S., Hiramatsu T., Hatano K.,Nagawa H.: Plasma adiponectin and gastric cancer. Clin. CancerRes., 2005; 11: 466-472
  Google Scholar
• 20. Ishikawa M., Kitayama J., Nagawa H.: Expression pattern of leptinand leptin receptor (OB-R) in human gastric cancer. World J. Gastroenterol.,2006; 12: 5517-5522
  Google Scholar
• 21. Ishikawa M., Kitayama J., Nagawa H.: Enhanced expression ofleptin and leptin receptor (OB-R) in human breast cancer. Clin. CancerRes., 2004; 10: 4325-4331
  Google Scholar
• 22. Karapanagiotou E.M., Tsochatzis E.A., Dilana K.D., TourkantonisI., Gratsias I., Syrigos K.N.: The significance of leptin, adiponectin,and resistin serum levels in non-small cell lung cancer (NSCLC).Lung Cancer, 2008; 61: 391-397
  Google Scholar
• 23. Kim H.J., Lee Y.S., Won E.H., Chang I.H., Kim T.H., Park E.S., KimM.K., Kim W., Myung S.C.: Expression of resistin in the prostate andits stimulatory effect on prostate cancer cell proliferation. BJU Int.,2011; 108: E77-E83
  Google Scholar
• 24. Koda M., Sulkowska M., Wincewicz A., Kanczuga-Koda L., MusiatowiczB., Szymanska M., Sulkowski S.: Expression of leptin, leptinreceptor, and hypoxia-inducible factor 1 alpha in human endometrialcancer. Ann. N Y Acad. Sci., 2007; 1095: 90-98
  Google Scholar
• 25. Kyriazi E., Tsiotra P.C., Boutati E., Ikonomidis I., FountoulakiK., Maratou E., Lekakis J., Dimitriadis G., Kremastinos D.T., RaptisS.A.: Effects of adiponectin in TNF-α, IL-6, and IL-10 cytokine productionfrom coronary artery disease macrophages. Horm. Metab.Res., 2011; 43: 537-544
  Google Scholar
• 26. Lee E.S., Park S.H., Kim M.S., Han S.Y., Kim H.S., Kang Y.H.: Caffeicacid disturbs monocyte adhesion onto cultured endothelialcells stimulated by adipokine resistin. J. Agric. Food Chem., 2012;60: 2730-2739
  Google Scholar
• 27. Matsuda A., Matsutani T., Sasajima K., Furukawa K., Tajiri T.,Tamura K., Kogo H.: Preoperative plasma adiponectin level is a riskfactor for postoperative infection following colorectal cancer surgery.J. Surg. Res., 2009; 157: 227-234
  Google Scholar
• 28. Michalakis K., Williams C.J., Mitsiades N., Blakeman J., Balafouta-TselenisS., Giannopoulos A., Mantzoros C.S.: Serum adiponectinconcentrations and tissue expression of adiponectin receptors arereduced in patients with prostate cancer: a case control study. CancerEpidemiol. Biomarkers Prev., 2007; 16: 308-313
  Google Scholar
• 29. Moschen A.R., Kaser A., Enrich B., Mosheimer B., Theurl M.,Niederegger H., Tilg H.: Visfatin, an adipocytokine with proinflammatoryand immunomodulating properties. J. Immunol., 2007; 178:1748-1758
  Google Scholar
• 30. Moschovi M., Trimis G., Vounatsou M., Katsibardi K., MargeliA., Damianos A., Chrousos G., Papassotiriou I.: Serial plasma concentrationsof adiponectin, leptin, and resistin during therapy inchildren with acute lymphoblastic leukemia. J. Pediatr. Hematol.Oncol., 2010; 32: e8-e13
  Google Scholar
• 31. Nakajima T.E., Yamada Y., Hamano T., Furuta K., Gotoda T., KataiH., Kato K., Hamaguchi T., Shimada Y.: Adipocytokine levels in gastriccancer patients: resistin and visfatin as biomarkers of gastriccancer. J. Gastroenterol., 2009; 44: 685-690
  Google Scholar
• 32. Nakajima T.E., Yamada Y., Hamano T., Furuta K., Matsuda T.,Fujita S., Kato K., Hamaguchi T., Shimada Y.: Adipocytokines as newpromising markers of colorectal tumors: adiponectin for colorectaladenoma, and resistin and visfatin for colorectal cancer. CancerSci., 2010; 101: 1286-1291
  Google Scholar
• 33. Otake S., Takeda H., Suzuki Y., Fukui T., Watanabe S., IshihamaK., Saito T., Togashi H., Nakamura T., Matsuzawa Y., Kawata S.: Associationof visceral fat accumulation and plasma adiponectin withcolorectal adenoma: evidence for participation of insulin resistance.Clin. Cancer Res., 2005; 11: 3642-3646
  Google Scholar
• 34. Pendyala S., Neff L.M., Suarez-Farinas M., Holt P.R.: Diet-inducedweight loss reduces colorectal inflammation: implicationsfor colorectal carcinogenesis. Am. J. Clin. Nutr., 2011; 93: 234-242
  Google Scholar
• 35. Reddy P.S., Umesh S., Thota B., Tandon A., Pandey P., Hegde A.S.,Balasubramaniam A., Chandramouli B.A., Santosh V., Rao M.R., KondaiahP., Somasundaram K.: PBEF1/NAmPRTase/visfatin: a potentialmalignant astrocytoma/glioblastoma serum marker with prognosticvalue. Cancer Biol. Ther., 2008; 7: 663-668
  Google Scholar
• 36. Rohla M., Weiss T.W.: Metabolic syndrome, inflammation andatherothrombosis. Hamostaseologie, 2013; 33: 283-294
  Google Scholar
• 37. Samal B., Sun Y., Stearns G., Xie C., Suggs S., McNiece I.: Cloningand characterization of the cDNA encoding a novel human preB-cellcolony-enhancing factor. Mol. Cell. Biol., 1994; 14: 1431-1437
  Google Scholar
• 38. Słomian G., Świętochowska E., Malinowska-Borowska J., KasperczykS., Rogalska A., Nowak P.: Association between chemotherapyand plasma adipokines in patients with colorectal cancer. Pharmacol.Rep., 2014; 66: 902-907
  Google Scholar
• 39. Tarkowski A., Bjersing J., Shestakov A., Bokarewa M.I.: Resistincompetes with lipopolysaccharide for binding to toll-like receptor
  Google Scholar
• 40. Tiaka E.K., Manolakis A.C., Kapsoritakis A.N., Potamianos S.P.:The implication of adiponectin and resistin in gastrointestinal diseases.Cytokine Growth Factor Rev., 2011; 22: 109-119
  Google Scholar
• 41. Tsatsanis C., Zacharioudaki V., Androulidaki A., Dermitzaki E.,Charalampopoulos I., Minas V., Gravanis A., Margioris A.N.: Adiponectininduces TNF-α and IL-6 in macrophages and promotes toleranceto itself and other pro-inflammatory stimuli. Biochem. Biophys.Res. Commun., 2005; 335: 1254-1263
  Google Scholar
• 42. Umekawa K., Kimura T., Kudoh S., Suzumura T., Nagata M., MitsuokaS., Matsuura K., Oka T., Yoshimura N., Kira Y., Hirata K.: Reactionof plasma adiponectin level in non-small cell lung cancerpatients treated with EGFR-TKIs. Osaka City Med. J., 2013; 59: 53-60
  Google Scholar
• 43. Verma S., Li S.H., Wang C.H., Fedak P.W., Li R.K., Weisel R.D.,Mickle D.A.: Resistin promotes endothelial cell activation: furtherevidence of adipokine-endothelial interaction. Circulation, 2003;108: 736-740
  Google Scholar
• 44. Wang B., Hasan M.K., Alvarado E., Yuan H., Wu H., Chen W.Y.:NAMPT overexpression in prostate cancer and its contribution totumor cell survival and stress response. Oncogene, 2011; 30: 907-921
  Google Scholar
• 45. Wei E.K., Giovannucci E., Fuchs C.S., Willett W.C., MantzorosC.S.: Low plasma adiponectin levels and risk of colorectal cancer inmen: a prospective study. J. Natl. Cancer Inst., 2005; 97: 1688-1694
  Google Scholar
• 46. Yang W.H., Chen J.C., Hsu K.H., Lin C.Y., Wang S.W., Wang S.J.,Chang Y.S., Tang C.H.: Leptin increases VEGF expression and enhancesangiogenesis in human chondrosarcoma cells. Biochim. Biophys.Acta, 2014; 1840: 3483-3493
  Google Scholar
• 47. Zemanová M., Staňková B., Ušiakova Z., Tvrzická E., Pazdro A.,Petruželka L., Zeman M.: Serum adiponectin relates to shortenedoverall survival in men with squamous cell esophageal cancer treatedwith preoperative concurrent chemoradiotherapy: a pilot study.Med. Sci. Monit., 2014; 20: 2351-2357
  Google Scholar
• 48. Zhou W., Guo S., Gonzalez-Perez R.R.: Leptin pro-angiogenicsignature in breast cancer is linked to IL-1 signalling. Br. J. Cancer,2011; 104: 128-137
  Google Scholar

Pełna treść artykułu